Oct 28, 2014

Farmak to launch Lira Oral Solution

Farmak expands its range of drugs for treatment of acute (stroke) and chronic cerebrovascular disorders – Lira (citicoline). The Company's experts have developed and launched Lira as 30 ml syrup.  

Farmak is actively working towards the treatment of cardiovascular and cerebrovascular diseases. In particular, it focuses on ensuring full-scale provision of proper quality and affordable treatment of acute and chronic cerebral circulation disorders in adults, and neurological diseases in children. To that end, the Company's experts have developed and launched the medicinal product Lira as 30 ml syrup.

The medicinal product is prescribed to adult patients in the acuity period and on the following states:

Lira Syrup can also be used to treat muscle hypertonia of the lower extremities in children, encephalopathy, infantile cerebral paralysis (ICP), traumatic brain injury, effects of neuroinfections, and ischemic conditions during prenatal development.

The course of treatment is at least 45 days.


Back to the News